Table 2. Incidence of Acute Highest-Grade Treatment-Related Toxic Effects 3 Months or Less After SBRTa.
| Adverse event | Patients, No. (%) (N = 154) | P valueb | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CT-guided SBRT (n = 76) | MRI-guided SBRT (n = 78) | ||||||||
| Grade 1 | Grade 2 | Grade 3 | Grade ≥2 | Grade 1 | Grade 2 | Grade 3 | Grade ≥2 | ||
| Genitourinary | |||||||||
| Anyc | 34 (44.7) | 32 (42.1) | 1 (1.3) | 33 (43.4) | 39 (50.0) | 19 (24.4) | 0 | 19 (24.4) | .006 |
| Cystitis | 2 (2.6) | 2 (2.6) | 0 | 2 (2.6) | 0 | 0 | 0 | 0 | .12 |
| Hematuria | 1 (1.3) | 1 (1.3) | 0 | 1 (1.3) | 2 (2.6) | 1 (1.3) | 0 | 1 (1.3) | .50 |
| Urinary frequency | 32 (42.1) | 24 (31.6) | 0 | 24 (31.6) | 28 (35.9) | 12 (15.4) | 0 | 12 (15.4) | .01 |
| Urinary incontinence | 9 (11.8) | 3 (3.9) | 0 | 3 (3.9) | 4 (5.1) | 2 (2.6) | 0 | 2 (2.6) | .34 |
| Urinary retention | 10 (13.2) | 20 (26.3) | 1 (1.3) | 21 (27.6) | 7 (9.0) | 9 (11.5) | 0 | 9 (11.5) | .006 |
| Urinary tract infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | .50 |
| Urinary urgency | 20 (26.3) | 9 (11.8) | 0 | 9 (11.8) | 19 (24.4) | 5 (6.4) | 0 | 5 (6.4) | .14 |
| Dysuria | 9 (11.8) | 5 (6.6) | 0 | 5 (6.6) | 1 (1.3) | 5 (6.4) | 0 | 5 (6.4) | .50 |
| Gastrointestinal | |||||||||
| Anyc | 34 (44.7) | 8 (10.5) | 0 | 8 (10.5) | 23 (29.5) | 0 | 0 | 0 | .001 |
| Colitis | 1 (1.3) | 2 (2.6) | 0 | 2 (2.6) | 0 | 0 | 0 | 0 | .12 |
| Constipation | 3 (3.9) | 0 | 0 | 0 | 3 (3.8) | 0 | 0 | 0 | .50 |
| Diarrhea | 22 (28.9) | 5 (6.6) | 0 | 5 (6.4) | 15 (19.2) | 0 | 0 | 0 | .01 |
| Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | .50 |
| Proctitis | 15 (19.7) | 5 (6.6) | 0 | 5 (6.4) | 9 (11.5) | 0 | 0 | 0 | .01 |
| GI hemorrhage | 4 (5.3) | 3 (3.9) | 0 | 3 (3.8) | 1 (1.3) | 0 | 0 | 0 | .06 |
| Rectal pain | 2 (2.6) | 2 (2.6) | 0 | 2 (2.6) | 1 (1.3) | 0 | 0 | 0 | .12 |
| Sexual | |||||||||
| Anyc | 2 (2.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | .50 |
| Erectile dysfunction | 2 (2.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | .50 |
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; SBRT, stereotactic body radiotherapy.
a
Toxic effects were graded according to Common Terminology Criteria for Adverse Events, version 4.03.
b
P values compare grade 2 or more toxic effects between the CT-guided and the MRI-guided SBRT arms, using χ2 or Fisher exact test when appropriate. One-sided P values presented with a significance threshold of .025.
c
Any genitourinary, gastrointestinal, or sexual toxic effect indicates the highest-grade adverse event in that domain for all patients. Patients may have experienced more than 1 category of adverse event.